Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
Status:
Withdrawn
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This study will determine the response rate of daily low dose interferon-alpha-2b in patients
with metastatic or unresectable clear cell renal cell carcinoma.